BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS
Quebec Innovative Materials:Advancing Canadian and American Natural Hydrogen for the Next Energy Cycle